Abstract

Mini Review

A decade of targeted therapy for non-small cell lung cancer

Khalid Abu Ajaj*

Published: 28 September, 2017 | Volume 1 - Issue 1 | Pages: 023-027

Chemotherapy is one of the main treatment options for cancer. However, chemotherapeutic agents usually suffer from poor pharmaceutical properties that restrict their use. Targeted therapy drugs have been developed to specifically target changes in cancer cells that help these cells to grow. Such drugs often work when standard chemotherapeutic drugs do not, they often have less severe side effects and they are most often used for advanced cancers. The objective of this article is to give an overview about the 16 FDA-approved targeted therapy drugs to treat non-small cell lung cancer.

Read Full Article HTML DOI: 10.29328/journal.jprr.1001005 Cite this Article Read Full Article PDF

References

  1. Dolly SO, Collins DC, Sundar R, Popat S, Yap TA. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs. 2017; 77: 813-827. Ref.: https://goo.gl/XjqRJw
  2. No Authors. FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer. Cancer Biol Ther. 2006; 5: 1425-1428. Ref.: https://goo.gl/wRvL5W
  3. Markham A. Brigatinib: First Global Approval. Drugs. 2017; 77: 1131-1135. Ref.: https://goo.gl/bEYp8G
  4. fda.gov.
  5. Horn L, Sandler A. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer. 2007; 8: 68-73. Ref.: https://goo.gl/bbKEXJ
  6. Hennequin C. Targeted therapies and radiotherapy in lung cancer. Cancer Radiother. 2007; 11: 77-83. Ref.: https://goo.gl/KFgHJm
  7. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015; 23: 32-38. Ref.: https://goo.gl/fr4u92
  8. Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des. 2006; 12: 387-394. Ref.: https://goo.gl/auKpiw
  9. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006; 28: 1779-1802. Ref.: https://goo.gl/dgq4Ud
  10. Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014; 7: 1997-2006. Ref.: https://goo.gl/VGbGe5
  11. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015; 8; 49-53. Ref.: https://goo.gl/m7YmSt
  12. Metro G, Finocchiaro G, Toschi L, Elisabetta M, Alessandra C, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials. 2006; 1: 1-13. Ref.: https://goo.gl/x25PLq
  13. Pillai RN, Ramalingam SS. Necitumumab: a new therapeutic option for squamous cell lung cancer? Transl Lung Cancer Res. 2014; 3: 382-383. Ref.: https://goo.gl/nCpDgg
  14. Fala L. Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2016; 9; 119-122. Ref.: https://goo.gl/gGFrbV
  15. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015; 51: 7-20. Ref.: https://goo.gl/eJCaXN
  16. Lim SH, Sun JM, Lee SH, Ahn JS, Park K, et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2016; 16: 397-406. Ref.: https://goo.gl/TPPqxn
  17. Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, He K, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017. Ref.: https://goo.gl/56EANN
  18. Krishnamurthy A, Jimeno A. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today (Barc). 2017; 53: 217-237. Ref.: https://goo.gl/vfSHk4
  19. Markham A. Atezolizumab: First Global Approval. Drugs. 2016; 76: 1227-1232. Ref.: https://goo.gl/uUc3un
  20. Flippot R, Fallet V, Besse B, Wislez M, Vignot S, et al. Nivolumab, a new hope in non-small cell lung cancer. Bull Cancer. 2015; 102: 1046-1052. Ref.: https://goo.gl/UnmCy2
  21. Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer with Progression on or After Platinum-Based Chemotherapy. Oncologist. 2016; 21: 634-642. Ref.: https://goo.gl/ErnYGR
  22. Takahama T, Sakai K, Takeda M, Azuma K, Hida T, et al. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget. 2016; 7: 58492-58499. Ref.: https://goo.gl/qdMcK5
  23. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017; 3: 001115. Ref.: https://goo.gl/w8W2wP
  24. Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10: 1396-403. Ref.: https://goo.gl/2SJBL4
  25. Takeda M, Nakagawa K. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer. Curr Cancer Drug Targets. 2015; 15: 792-802. Ref.: https://goo.gl/tCiSYs
  26. Ostoros G, Dome B. [Erlotinib in the treatment of non-small cell lung cancer]. Magy Onkol. 2006; 50: 237-241. Ref.: https://goo.gl/vdVRUy
  27. Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010; 15: 1344-1351. Ref.: https://goo.gl/Ue64Uj
  28. Khozin S, Gideon M. Blumenthal, Xiaoping Jiang, Kun He, Karen Boyd, et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist. 2014; 19: 774-779. Ref.: https://goo.gl/gRPh6T
  29. Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013; 6: 135-143. Ref.: https://goo.gl/Z5X565
  30. Dungo RT, Keating GM. Afatinib: first global approval. Drugs. 2013; 73: 1503-1515. Ref.: https://goo.gl/5iW5ny
  31. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010; 11: 1343-1357. Ref.: https://goo.gl/JDPmM8
  32. No author listed. Gefitinib Approved for EGFR-Mutated NSCLC. Cancer Discov. 2015; 5: 896. Ref.: https://goo.gl/MrygSG
  33. McCoach CE, Jimeno A. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today (Barc). 2016; 52: 561-568. Ref.: https://goo.gl/oUoXud
  34. Greig SL. Osimertinib: First Global Approval. Drugs. 2016; 76: 263-273. Ref.: https://goo.gl/naWk1f
  35. Ou SH. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012; 12: 151-162. Ref.: https://goo.gl/ojZoKx
  36. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011; 9: 1335-1341. Ref.: https://goo.gl/qPGzc7
  37. Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016; 469: 489-503. Ref.: https://goo.gl/uRyTWQ
  38. Cooper MR, Chim H, Chan H, Durand C. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Ann Pharmacother. 2015; 49: 107-112. Ref.: https://goo.gl/xYRmGt
  39. Guha M. Novartis' lung cancer ALK inhibitor approved. Nat Biotechnol, 2014; 32: 607. Ref.: https://goo.gl/aP2c6g
  40. Avrillon V, Perol M. Alectinib for treatment of ALK-positive non-small-cell lung cancer. Future Oncol. 2017; 13: 321-335. Ref.: https://goo.gl/6A5Gfp
  41. Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, et al. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib. Clin Cancer Res. 2016; 22: 5171-5176. Ref.: https://goo.gl/2KALyE
  42. Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, et al. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016; 7: 29011-29022. Ref.: https://goo.gl/d1cbXg
  43. Asati V, Bharti SK, Mahapatra DK. Mutant B-Raf Kinase Inhibitors as Anticancer Agents. Anticancer Agents Med Chem. 2016; 16: 1558-1575. Ref.: https://goo.gl/VdGM8T
  44. Smida M, Fece de la Cruz F, Kerzendorfer C, Uras IZ, Mair B, et al. MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nat Commun. 2016; 7: 13701. Ref.: https://goo.gl/oGb69r

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More